Updated: Nov 3
In June 2026, China's drug regulator approved what is reported as the world's first CAR-T cell therapy for a solid tumor. The treatment, satri-cel, targets a protein called Claudin18.2 in advanced stomach cancer. Its key trial was led out of Peking University Cancer Hospital (OncLive, June 2026).
For international patients, that milestone raises a practical question: which Chinese cancer centers are actually worth considering, and for which cancers? China has hundreds of large hospitals. Only a handful lead the clinical research that changes treatment.
The short answer: five centers stand out — the National Cancer Center / Cancer Hospital, Chinese Academy of Medical Sciences (Beijing), Fudan University Shanghai Cancer Center, Sun Yat-sen University Cancer Center (Guangzhou), Peking University Cancer Hospital (Beijing) and Ruijin Hospital (Shanghai) for blood cancers. Each has led published trials in specific cancers. Which one is right depends on your diagnosis.
Key Takeaways |
|
Table of Contents
How We Selected China's Top Cancer Centers
Thanks to the Fudan China Hospital Rankings as an authoritative reference in China, three things: leadership of peer-reviewed clinical trials, depth in specific cancer types, and experience with patients from outside mainland China were evaluated. Size alone was not enough.
We deliberately spread the list across Beijing, Shanghai and Guangzhou and across tumor types. A list of five "best" hospitals that all excel in the same cancer would be of little use to most readers.
1. National Cancer Center / Cancer Hospital, Chinese Academy of Medical Sciences (Beijing)
Founded in 1958 and designated China's National Cancer Center in 2011, this hospital has about 1,500 beds and handles roughly 1.02 million outpatient visits and 32,000 operations a year (Wikipedia). It also sets many of China's national cancer guidelines.
A standout result: HER2-positive breast cancer. Prof. Binghe Xu led the PHOEBE phase III trial of pyrotinib, a Chinese-developed targeted drug, against lapatinib (both with capecitabine) in 266 previously treated patients. Median overall survival was 39.4 months versus 28.6 months (HealthDay via Drugs.com, Nov 2023). The study was funded by the drug's developer, Jiangsu Hengrui.
Best for: a broad range of solid tumors, especially lung, esophageal and breast cancer, and patients who want a center that shapes national standards.
2. Fudan University Shanghai Cancer Center (Shanghai)
Founded in 1931, FUSCC is China's first dedicated cancer hospital, with about 1,100 beds (Wikipedia).
A standout result: precision treatment for triple-negative breast cancer. In the FUTURE phase II trial, FUSCC matched 141 heavily pretreated patients to drugs based on their tumor's molecular subtype. 29.8% saw significant tumor shrinkage, with median overall survival of 10.7 months and no treatment-related deaths (Cell Research, 2023). This is research, not routine care.
Best for: breast, gynecologic, and head and neck cancers, and other solid tumors. Top 3 Cancer Hospitals in Shanghai
3. Sun Yat-sen University Cancer Center (Guangzhou)
Founded in 1964, SYSUCC has about 1,488 beds and has been a sister institution of MD Anderson Cancer Center since 2003 (China Services Info).
A standout result: nasopharyngeal carcinoma (NPC). In a 480-patient phase III trial led by Prof. Jun Ma, adding induction chemotherapy before chemoradiation raised three-year overall survival from 90.3% to 94.6% (Sun Yat-sen University, 2019; NEJM). SYSUCC also led the ESCORT-1st trial in advanced esophageal cancer, where adding the PD-1 drug camrelizumab to chemotherapy improved median overall survival from 12.0 to 15.3 months (CancerNetwork, 2021).
Best for: NPC and other head and neck cancers, esophageal and gastrointestinal cancers. Guangzhou Cancer Hospitals 2026: How to Choose
4. Peking University Cancer Hospital (Beijing)
Peking University Cancer Hospital is a leading center for gastrointestinal cancers and early-phase cell therapy research.
A standout result: the first solid-tumor CAR-T approval. In the randomized phase II CT041-ST-01 trial, 156 patients with advanced Claudin18.2-positive stomach or gastroesophageal junction cancer received either satri-cel or their doctor's choice of treatment. Median progression-free survival was 3.25 months versus 1.77 months, a 63% reduction in the risk of progression or death (OncLive, June 2026; Lancet 2025).
Be realistic about this result. The gain in progression-free survival is measured in weeks, not years. Cytokine release syndrome occurred in 95% of treated patients, and nearly all had serious drops in blood counts. Approval covers only patients whose cancer is Claudin18.2-positive, HER2-negative and has progressed after at least two prior lines of treatment.
Best for: stomach, colorectal and other gastrointestinal cancers, and patients exploring cell therapy after standard options.
5. Ruijin Hospital (Shanghai): Blood Cancers
Solid-tumor centers are not always the best place for leukemia, lymphoma or myeloma. Ruijin Hospital, home of the Shanghai Institute of Hematology, helped develop the arsenic-based treatment for acute promyelocytic leukemia. In 85 patients, five-year overall survival was 91.7% (PNAS 2009), and this approach is now standard worldwide.
Ruijin also ran an early trial of a BCMA-targeted CAR-T therapy for multiple myeloma, with about a 90% response rate in 17 patients (China Daily, 2019).
Best for: leukemia, lymphoma, myeloma, and blood cancer CAR-T.
Photos and profiles: the hospitals and their affiliated university sources.
Which Chinese Cancer Center Fits Your Diagnosis?
On cost: we don't publish price ranges, because they vary widely by treatment. CAR-T in particular is expensive in every country. Ask for a written, itemized estimate.
Notable Private Cancer Hospitals in China
Alongside the public academic centers above, China has a growing number of private hospitals that focus on cancer and actively serve international patients. Most are known for one specific technology or treatment area rather than broad, trial-led cancer care. A few are worth knowing about.
Beijing GoBroad Boren Hospital (Beijing): CAR-T for blood cancers. Boren is the private hospital on this list with the strongest published evidence. In a first-in-human phase I trial of donor-derived CD7 CAR-T cells for relapsed or refractory T-cell acute lymphoblastic leukemia, a cancer with few options, 18 of 20 patients (90%) achieved complete remission (ASCO Post, 2021; Journal of Clinical Oncology). All patients had cytokine release syndrome, 60% developed mild graft-versus-host disease, and one died of a fungal infection. Its parent group, GoBroad Healthcare, reports more than 4,000 bone marrow transplants across its hospitals (GoBroad via My1Health), a figure that has not been independently verified.
Concord Cancer Centers (Guangzhou and Shanghai): proton therapy. Concord Medical opened Guangzhou Concord Cancer Center in 2021 with a pencil-beam proton therapy system (Concord Medical, 2021), and in July 2025 reported China's first proton treatment for choroidal melanoma, an eye cancer (Concord Healthcare, 2025).
Fuda Cancer Hospital (Guangzhou): tumor ablation. Founded in 2001, Fuda is known for cryoablation (freezing tumors) and NanoKnife, and reports more than 10,000 cryotherapy cases with a large share of foreign patients (SCMP). Other Chinese oncologists have noted these techniques are unsuitable for tumors near major vessels, the stomach or the brain.
St. Stamford Modern Cancer Hospital (Guangzhou): international services. A China–Singapore joint venture, it was the first such venture in China accredited by Joint Commission International (JCI) (Perennial Holdings), and emphasizes minimally invasive and interventional treatments.
Lu Daopei Hospitals (Beijing, Hebei and Shanghai): blood cancers and transplantation. This private hematology network treats leukemia, lymphoma and myeloma, with programs in hematopoietic stem-cell transplantation and CAR-T therapy. It excels in multidisciplinary blood-cancer care. Confirm the appropriate campus, the specific treatment and eligibility before travel.
Guangzhou RoyalLee Cancer Hospital: oncology and international services. RoyalLee is a privately operated tertiary oncology hospital in Guangzhou. Its has cancer care for international patients, including interventional and minimally invasive treatments. Ask for the proposed treatment’s evidence, the responsible clinical team and a written care plan for your diagnosis.
Public Academic Centers vs. Private Cancer Hospitals in China
How to use this comparison: a private hospital can be the right choice when its specialty matches your need, such as CAR-T for a relapsed blood cancer. Be cautious if any hospital proposes a local treatment like ablation in place of systemic therapy that guidelines recommend for your cancer. Ask: Is this in NCCN or ESMO guidelines for my cancer? What are your own published results for patients like me?
What International Patients Should Know Before Choosing a Center in China
"Approved in China" does not mean "approved where you live." Several drugs above are approved by China's NMPA but not by the FDA or EMA. That can be an opportunity, but your home doctor may be unfamiliar with them and follow-up needs planning.
Your biomarkers decide what's on the table. Satri-cel requires Claudin18.2 testing; pyrotinib requires HER2 positivity. Without the right test results, no center can tell you whether you qualify.
Choosing the city is part of the decision. Beijing, Shanghai and Guangzhou differ in flight access, climate and international services. Advanced treatments like CAR-T may require four to eight weeks nearby for monitoring.
Independent Guidance Before You Travel
ChinaCureLink (chinacurelink.com), a Medebound HEALTH company, is an independent medical facilitator and patient advocate helping international patients explore serious disease treatment in the US or in China. Founded by physicians 10 years ago, it has helped around 3,000 international patients.
With five strong centers in three cities, the hardest step is often knowing where to start. ChinaCureLink represents the patient, not any hospital. Its team reviews your diagnosis, pathology and biomarkers, matches your case with up to three relevant Chinese hospitals, and can help arrange a video second opinion with a Chinese specialist before you decide whether to travel. Our hospital and specialist matching service is free. Video second opinions are separate paid specialist consultations; the fee will be confirmed before booking.
Your Next Steps
Frequently Asked Questions
What is the best cancer hospital in China? The Cancer Hospital, Chinese Academy of Medical Sciences is China's National Cancer Center and the broadest national reference. But the best hospital for you depends on your cancer: SYSUCC for nasopharyngeal cancer, Ruijin for blood cancers, and Peking University Cancer Hospital for Claudin18.2 CAR-T, for example.
Does China offer CAR-T therapy for solid tumors? Yes. In June 2026, China approved satri-cel for Claudin18.2-positive, HER2-negative advanced stomach and gastroesophageal junction cancer after at least two prior treatments. Other solid-tumor CAR-T therapies remain in clinical trials.
Can foreigners be treated at China's top cancer centers? Yes, these centers treat international patients. Access to clinical trials is more limited and depends on each study's rules.
Are Chinese cancer drugs approved outside China? Some are. Toripalimab, developed in China, is approved in the US for nasopharyngeal cancer. Others, such as pyrotinib, are approved mainly in China. Check each drug's status in your own country.
The Bottom Line
China's top cancer centers have produced practice-changing results in specific cancers: nasopharyngeal carcinoma, HER2-positive breast cancer, esophageal cancer, blood cancers, and now the first approved solid-tumor CAR-T. Those strengths are real but narrow. For many cancers, outcomes may be similar to good care at home.
The most useful next step is to find out whether one of these strengths matches your diagnosis, through a specialist review of your records before any travel.
About ChinaCureLink
ChinaCureLink (chinacurelink.com), a Medebound HEALTH company, is an independent medical facilitator and patient advocate helping international patients explore serious disease treatment in the US or in China. Founded by physicians 10 years ago, it has helped around 3,000 international patients.
Medical Disclaimer
This guide provides general information and does not replace medical advice from your treating clinician. Eligibility, treatment access, risks, fees and follow-up require individual assessment. Research findings and patient stories do not guarantee outcomes. Confirm the proposed plan directly with the hospital before travel.
